Greenland Mines Ltd

Greenland Mines Ltd. announced a direct registered offering to sell an aggregate of 1,765,420 shares of common stock and 1,434,580 pre-funded warrants at an offering price of $12.00 per share. The company expects to raise approximately $38.4 million in net proceeds, which will be used for its mining operations, general corporate purposes, and working capital. The offering is expected to close on September 24, 2026. Additionally, the company amended its private warrants to change the post-reverse split exercise price to $5.00 per share.

Greenland Mines Ltd announced the commencement of drilling operations at its Skaergaard gold, palladium, and platinum project in southeast Greenland. The support vessel Argus successfully arrived, and all equipment and infrastructure were mobilized ashore. Safety inductions were completed, and drill rigs are now running, with the first holes expected to be completed within days, marking the full operational start of the 2026 field season.

Greenland Mines Ltd. announced that its Special Meeting of Stockholders, originally convened on July 16, 2026, and previously adjourned to August 7, 2026, has been further adjourned. The reconvened meeting on August 7, 2026, was adjourned without conducting any additional business to September 3, 2026, at 1:00 p.m. Eastern Time. The record date for the meeting remains May 18, 2026, and no vote was taken at the August 7 meeting.

Greenland Mines Ltd announced the official start of its 2026 field season for the Skaergaard Project, with the support vessel Argus departing Reykjavik for southeast Greenland. The program involves a team of over 40 experts and a full fleet of equipment for drilling, bulk sampling, and geophysical surveys. This comprehensive effort also includes an expanded environmental and engineering program, designed to advance Skaergaard toward its next phase of development, including potential open-pit mining scenarios.

Greenland Mines Ltd announced that Innovation, Science and Economic Development Canada has granted Patent No. CA3,005,398, titled "SECRETED SPLICING VARIANT OF MAMMAL KLOTHO AS A MEDICAMENT FOR COGNITION AND MEMORY." This patent protects the use of a human gene therapy utilizing a nucleic acid gene sequence encoding the secreted Klotho (s-KL) protein, with 42 claims covering its utility in treating various neurodegenerative diseases. The company now holds patents for its product candidate KLTO-101 in all major markets, and KLTO-101 is set to begin process development and manufacturing in August 2026. Additionally, KLTO-202 for ALS and other neuromuscular disorders has advanced to the GMP manufacturing stage.

Greenland Mines Ltd. announced the adoption of a limited-duration stockholder rights plan, effective July 22, 2026. The Board declared a dividend of one right for each outstanding common share, payable on August 7, 2026. This plan is intended to protect shareholder value by deterring coercive takeover tactics and ensuring all stockholders receive fair value, allowing the Board time to make informed decisions. The rights become exercisable if a person or group acquires 15% or more of the outstanding shares, enabling other holders to purchase additional shares at a significant discount.

Greenland Mines Ltd. held a Special Meeting of stockholders on July 16, 2026, where Proposal 3, the Adjournment Proposal, was approved. This proposal allows for the meeting to be adjourned to a later date if necessary. Following the approval, the Special Meeting was adjourned until August 7, 2026, at 1:00 PM ET, to consider and vote on the remaining proposals.

Greenland Mines Ltd announced a significant update to the Mineral Resource Estimate (MRE) for its Skaergaard precious and critical metals project in southeast Greenland. The 2026 MRE, compliant with S-K 1300, shows a 31% increase in Indicated PdEq contained metal to 15.00 Moz and a 36% increase in Indicated PdEq grade to 3.04 g/t. This upgrade is attributed to updated metal prices, including gold at $3,500/oz, and an improved geological model, positioning Skaergaard as one of the largest undeveloped palladium, gold, and platinum resources in the western world.

Greenland Mines Ltd announced a significant update to the Mineral Resource Estimate (MRE) for its Skaergaard precious and critical metals project. The 2026 MRE, now compliant with SEC's S-K 1300, shows a 31% increase in Indicated PdEq contained metal to 15.00 Moz and a 36% increase in Indicated PdEq grade to 3.04 g/t. These improvements, driven by a more robust geological model and current metal prices, position Skaergaard as a major undeveloped resource. The company plans to move forward with an Initial Assessment, including evaluation of open-pit mining options.

Greenland Mines Ltd's Biotech Division announced that IP Australia has granted Australian Patent No. 2023252508, titled "Treatment of Neuromuscular Diseases via Gene Therapy that Expresses Klotho Protein." This patent covers technology exclusively licensed by the company, protecting the use of human gene therapy with a muscle-cell specific promoter for treating motor impairment. CEO Dr. Joseph Sinkule stated that this strengthens the intellectual property protecting their Klotho-based therapeutic platform and supports the advancement of KLTO-202 toward clinical development for ALS and other debilitating neuromuscular diseases.